Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
31.44
+0.14 (+0.45%)
Streaming Delayed Price
Updated: 11:05 AM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
March 02, 2023
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.
Via
The Motley Fool
3 Best Growth Stocks to Buy In March
March 02, 2023
These three red-hot growth stocks have more room to run.
Via
The Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
February 27, 2023
Via
Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
February 23, 2023
Via
Benzinga
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
February 23, 2023
Via
Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
February 21, 2023
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.
Via
Investor's Business Daily
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
January 26, 2023
Via
Benzinga
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
February 15, 2023
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.
Via
Talk Markets
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
February 10, 2023
Via
Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
February 07, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
February 02, 2023
Via
Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
January 19, 2023
Via
Benzinga
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...
Via
Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
January 12, 2023
Via
Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
January 09, 2023
Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.
Via
Investor's Business Daily
Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today
January 06, 2023
Benzinga
Via
Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
January 06, 2023
Via
Benzinga
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
January 05, 2023
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall.
Via
Investor's Business Daily
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
January 02, 2023
Which of these companies is better able to replace declining COVID-19-related sales?
Via
The Motley Fool
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
December 28, 2022
Investors are closely watching two key spaces that could spark Lilly stock.
Via
Investor's Business Daily
Roche's Follicular Lymphoma Therapy Scores FDA Approval
December 23, 2022
Via
Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
December 22, 2022
Via
Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
December 21, 2022
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...
Via
Talk Markets
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
December 20, 2022
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock.
Via
InvestorPlace
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
December 20, 2022
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche.
Via
Investor's Business Daily
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 13, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.
Via
Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
December 12, 2022
Via
Benzinga
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
December 12, 2022
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.